Apixaban in atrial fibrillation: does predicted risk matter?

Lancet. 2012 Nov 17;380(9855):1718-20. doi: 10.1016/S0140-6736(12)61673-0. Epub 2012 Oct 2.

Authors

Vassilis S Vassiliou¹, Paul D Flynn

Affiliation

¹ Papworth Hospital, Cambridge University Health Partners, Papworth Everard, Cambridge CB23 8RE, UK. vassiliou@doctors.org.uk

PMID: 23036897
DOI: 10.1016/S0140-6736(12)61673-0

No abstract available

Publication types

Comment

MeSH terms

Anticoagulants / therapeutic use*
Hemorrhage / prevention & control*
Humans
Male
Pyrazoles / therapeutic use*
Pyridones / therapeutic use*
Stroke / prevention & control*
Warfarin / therapeutic use*

Substances

Anticoagulants
Pyrazoles
Pyridones
apixaban
Warfarin